TrialCancer2018
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Glenwood D Goss et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
37 papers cite it
this papertrialcites it